Medication approval journey

zolpidem (Ambien)

Approved for Short-term treatment of insomnia

page first published · last updated

Also answers to “the 3am alibi” — its codename in our videos and posts. The full codebook

FDA approvedZ-drug sleep medicationTaper risk: high

How this page reads

The page as written, with the clinical terms

Plain language uses the same facts, the same numbers and the same caveats. It does not leave anything out. Quotes from the FDA label are never reworded in either setting.

Before you stop or change your zolpidem dose

Stopping abruptly can be dangerous — never do it without medical supervision

Z-drugs act on the same receptor system as benzodiazepines. Stopping abruptly after regular use can cause severe rebound insomnia and, at higher doses, seizures. Any change should be a prescriber-supervised taper.

what the zolpidem warnings mean

label facts below are read from the ambien (zolpidem tartrate) FDA label on DailyMed, set id c36cadf4-65a4-4466-b409-c82020b42452, version 26, effective april 15, 2025. the section numbers in brackets are the label’s own. every source is linked at the end of this section. last checked 2026-10-05.

zolpidem was approved in 1992 for the short-term treatment of insomnia, and about 2.4 million americans filled a prescription for it in 2024 [meps]. it is a schedule iv controlled substance. its label carries one boxed warning, added in 2019, and nine further warnings, and it has had one regulator-ordered dose change, in 2013. this section says what each means in plain words, what the approval trials measured and for how long, which side effects the label counts and how often, and what independent research has found since, in both directions. every number is from the label, an fda safety communication, or a study in the library, and each source is linked at the end.

this is information to take to a prescriber. nothing here is a reason to start, stop or change a dose on your own; the label lists withdrawal effects after rapid dose reduction.

the boxed warning: complex sleep behaviors (added 2019)

the boxed warning says that complex sleep behaviors, including sleep-walking, sleep-driving and doing other things while not fully awake, may occur after the first or any later dose, that some have caused serious injuries including death, and that the drug should be stopped immediately if one happens [label, boxed warning and 5.1]. the label adds preparing and eating food, making phone calls and having sex to the list, says people usually do not remember the event, and says it has happened at recommended doses with or without alcohol or other sedatives.

the warning is also a contraindication: anyone who has had a complex sleep behavior on zolpidem is not to take it again [label 4]. the fda added the boxed warning in april 2019, twenty-seven years after approval, after reports of sleep-walking and sleep-driving that caused serious injuries and deaths; the same action made the drugs contraindicated for anyone who had ever had such an episode on them [fda-2019].

what the warning does not say: how often it happens. the label describes post-marketing reports, which cannot give a rate. the trial side-effect tables below do not list these events at all, which is a limit of trials that ran a few weeks in a few hundred people, not evidence they are rare.

the 2013 dose change for women, and the morning-after warning

in january 2013 the fda halved the recommended starting dose for women, from 10 mg to 5 mg for the immediate-release tablet and from 12.5 mg to 6.25 mg for extended-release, because blood levels the next morning can remain high enough to impair driving and alertness, and women clear the drug more slowly [fda-2013]. the current label carries that change: the recommended starting dose is 5 mg for women and 5 or 10 mg for men, taken once, immediately before bed, with at least 7 to 8 hours remaining before waking; the total must not exceed 10 mg; and the dose is 5 mg for anyone elderly or with mild to moderate liver impairment [label 2.1, 2.2].

the warning behind the dose change is 5.2. the risk of next-day impairment, including impaired driving, is higher if the drug is taken with less than a full night of sleep left, at more than the recommended dose, with alcohol or other sedatives, or with drugs that raise zolpidem levels. the label says to warn drivers and machine operators about drowsiness, slowed reactions, blurred or double vision and impaired driving the morning after, and notes that older people are at higher risk of falls [label 5.2]. in the label’s own driving-related studies, a small but statistically significant drop in performance on a symbol-substitution test was seen the next day in healthy adults and in elderly subjects, while studies in non-elderly insomnia patients did not detect next-day effects [label 14.3].

the other warnings, in plain words

the rest of the warnings section runs from 5.3 to 5.9. none is boxed.

  • look for the cause [5.3]: insomnia can be the first sign of a medical or psychiatric illness. the label says that if insomnia has not settled after 7 to 10 days of treatment, that may point to a condition that should be looked for, and that new thinking or behavior changes may mean the same.
  • severe allergic reactions [5.4]: swelling of the tongue, throat or voice box, sometimes with breathlessness or throat closing, has been reported after the first or later doses, and can block the airway. anyone who has had this is not to take the drug again.
  • abnormal thinking and behavior [5.5]: decreased inhibition, out-of-character aggressiveness or extroversion, bizarre behavior, agitation and depersonalization have been reported, as have visual and auditory hallucinations; under 1% of adults in the 10 mg trials reported hallucinations, against 7% of children in a pediatric trial of a drug not approved for children. post-marketing reports include delirium. any new behavior change calls for prompt evaluation.
  • depression [5.6]: in people treated mainly for depression, sedative-hypnotics have been followed by worsening depression and suicidal thoughts and actions, including completed suicides; intentional overdose is more common in this group, so the label says to prescribe the smallest feasible number of tablets.
  • breathing [5.7]: 10 mg did not depress breathing in healthy people or in mild to moderate copd, but in people with mild to moderate sleep apnea it reduced the lowest oxygen level and lengthened time below 80% and 90% saturation. post-marketing reports of respiratory insufficiency mostly involved people with existing breathing problems. the label says to weigh this risk in sleep apnea, myasthenia gravis and anyone also on opioids.
  • liver [5.8]: the drug is cleared more slowly in liver disease and can tip hepatic insufficiency into encephalopathy; avoid in severe liver impairment.
  • withdrawal [5.9]: withdrawal signs and symptoms have followed rapid dose reduction or abrupt stopping. the label says to monitor for tolerance, abuse and dependence.
  • dependence and abuse [9]: schedule iv. physical or psychological dependence can develop, and the risk rises with dose and duration and with a history of alcohol or drug problems. in former drug abusers a single 40 mg dose produced effects similar to diazepam 20 mg, while 10 mg was hard to tell from placebo. the label says long-term use is not recommended and treatment should be as short as possible [label 2.1, 9.2, 9.3].

what the trials measured, and for how long

the approval rested on sleep-laboratory trials. in transient insomnia: 462 healthy adults in a single-night trial of 7.5 and 10 mg against placebo, and 35 healthy elderly adults in a two-night crossover of 5, 10, 15 and 20 mg, with zolpidem better than placebo on time to fall asleep, sleep duration and awakenings [label 14.1]. in chronic insomnia: 75 outpatients over 5 weeks, where 10 mg beat placebo on time to fall asleep for the first 4 weeks and on sleep efficiency in weeks 2 and 4 but was "comparable to placebo on number of awakenings"; and 141 outpatients over 4 weeks, where 10 mg beat placebo on self-reported time to fall asleep for all 4 weeks and on total sleep time, awakenings and sleep quality for the first week only [label 14.2].

the arithmetic that matters: the longest controlled trial behind the approval ran 5 weeks; the approved indication is short-term treatment; the label says long-term use is not recommended and that the risk of dependence rises with duration; and the one head-to-head measure of what the drug does in the lab is minutes of sleep latency, not hours of sleep. the open-questions step further down this page asks what happens on nightly use for years, which no trial behind the approval measured.

the most common side effects, with the label’s numbers

in the short trials, up to 10 nights, 685 people on zolpidem were compared with 473 on placebo; the reactions reported by at least 1% and more often than placebo were headache 7% vs 6%, drowsiness 2%, dizziness 1% and diarrhea 1% [label 6.1, table 1]. in the three longer trials of 28 to 35 nights, 152 people on up to 10 mg were compared with 161 on placebo: drowsiness 8% vs 5%, dizziness 5% vs 1%, allergy 4% vs 1%, sinusitis 4% vs 2%, dry mouth 3% vs 1%, lethargy 3% vs 1%, drugged feeling 3%, back pain 3% vs 2%, diarrhea 3% vs 2%, sore throat 3% vs 1%, palpitation 2%, depression 2% vs 1%, amnesia 1% [label 6.1, table 2]. the full list is in the side-effects section lower on this page.

in people aged 60 and over, the reactions at 3% or more and twice placebo were dizziness 3% vs 0%, drowsiness 5% vs 2% and diarrhea 3% vs 1%; among 1,959 older patients in non-us trials, 30 reported falls, 28 of them aged 70 or over and 23 of those on doses above 10 mg [label 8.5]. the label also reports next-morning memory loss for information presented at peak drug effect in a study of 10 and 20 mg doses, with adverse-event reports of anterograde amnesia mostly above 10 mg [label 14.3].

one caution the label attaches to all of these: the figures "cannot be used to predict the incidence of side effects in the course of usual medical practice", where people are older, take more drugs and use the medicine for longer than trial volunteers did.

what independent research says, in both directions

in favour. the drug does what the label says, measurably: across 13 placebo-controlled trials submitted to the fda (4,378 people), z-drugs including zolpidem shortened lab-measured time to fall asleep by about 22 minutes against placebo, with a large share of the improvement also occurring on placebo [huedo-medina-2012]. in a network meta-analysis of 154 double-blind randomised trials (44,089 people), zolpidem and similar drugs improved sleep in the short term [de-crescenzo-2022]. the label’s own studies found no polysomnographic rebound insomnia at recommended doses on the nights after stopping, and no consistent next-day memory impairment at 10 mg in adults [label 14.3].

against, or smaller than the badge suggests. the same network meta-analysis found that for longer-term treatment eszopiclone and lemborexant showed the more favourable balance of benefit and tolerability, and that long-term data for zolpidem were limited [de-crescenzo-2022]. pooling 14 observational studies of 830,877 older adults, z-drug use went with 1.63 times the odds of fractures, and zolpidem specifically with about twice the odds of injury (odds ratio 2.05, in 160,502 people) [treves-2018]. the uk guideline nice ng215 covers z-drugs alongside benzodiazepines and antidepressants: withdrawal can take months, medicines should not be stopped abruptly except in exceptional circumstances, and tapers should get smaller as the dose gets lower [nice-2022].

on interactions, the label is the source: alcohol and other cns depressants add to zolpidem’s effects, including impaired driving the next morning; opioids add respiratory depression risk; imipramine and chlorpromazine each worsened next-day alertness in single-dose studies; and rifampin or st john’s wort can reduce zolpidem’s effect by speeding its clearance, while ketoconazole can increase it [interactions]. the interaction most people will meet is the first one.

questions to ask your prescriber about zolpidem

each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.

  • if i ever sleep-walk, drive, eat or do anything i do not remember after taking zolpidem, the label says stop immediately. who do i call, and what do we do about the next night?
  • i am a woman on 10 mg. the fda’s recommended starting dose for women has been 5 mg since 2013. is there a reason i am on the higher dose?
  • do i reliably have 7 to 8 hours before i need to be up, and do i ever drive the next morning?
  • the approved use is short-term and the longest trial ran 5 weeks. how long have i been taking it, and what is the plan?
  • do i drink alcohol or take opioids, benzodiazepines, antihistamines or other sedatives on the same night?
  • i am over 65. given the doubled injury odds in the observational studies, is there a safer approach for me, or a reason this is still right?
  • if i want to stop, how do we taper, and how would we tell rebound insomnia from the original problem?

questions people ask

does zolpidem (ambien) have a black box warning?
yes, since april 2019: complex sleep behaviors, including sleep-walking, sleep-driving and other activities while not fully awake, which have caused serious injuries and deaths. the label says to stop the drug immediately if one occurs, and anyone who has had one on zolpidem is contraindicated from taking it again. the warning was added twenty-seven years after approval.
why is the zolpidem dose different for women?
in january 2013 the fda halved the recommended starting dose for women, from 10 mg to 5 mg for the immediate-release tablet and from 12.5 mg to 6.25 mg for extended-release, because next-morning blood levels can remain high enough to impair driving and alertness and women clear the drug more slowly. the current label says 5 mg for women, 5 or 10 mg for men, 5 mg for anyone elderly or with mild to moderate liver impairment, and never more than 10 mg a night.
what are the most common zolpidem side effects?
in the label’s longer trials (28 to 35 nights, 152 people on zolpidem vs 161 on placebo): drowsiness 8% vs 5%, dizziness 5% vs 1%, allergy 4% vs 1%, sinusitis 4% vs 2%, dry mouth 3% vs 1%, lethargy 3% vs 1%, a drugged feeling 3%. in short trials of up to 10 nights only headache (7% vs 6%), drowsiness, dizziness and diarrhea exceeded placebo. the label says these figures cannot predict rates in ordinary practice.
how much does zolpidem actually help you sleep?
in the fda-submitted trials pooled by independent researchers, z-drugs including zolpidem shortened lab-measured time to fall asleep by about 22 minutes compared with placebo, with much of the overall improvement also seen on placebo. the label’s own 5-week trial found 10 mg beat placebo on time to fall asleep but was comparable to placebo on the number of awakenings.
is zolpidem addictive, and what happens if you stop?
zolpidem is a schedule iv controlled substance. the label says physical or psychological dependence can develop, the risk rising with dose and duration and with a history of alcohol or drug problems, and that withdrawal signs have followed rapid dose reduction or abrupt stopping. it says long-term use is not recommended. in former drug abusers a 40 mg dose resembled diazepam 20 mg while 10 mg was hard to tell from placebo. the uk guideline says coming off should be a gradual, stepped taper. that plan belongs with a prescriber.

sources for this section

the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.

  1. ambien (zolpidem tartrate) tablets prescribing information, fda label on dailymed (set id c36cadf4-65a4-4466-b409-c82020b42452, version 26, effective april 15, 2025): boxed warning; sections 2.1, 2.2, 4, 5.1 to 5.9, 6.1 tables 1 and 2, 8.5, 9, 14.1 to 14.3
  2. ahrq medical expenditure panel survey, prescribed medicines public-use file 2024 (hc-254a): people with at least one zolpidem purchase, weighted; computed by veisund, method on the usage section of this page
  3. fda drug safety communication, april 2019: boxed warning added to zolpidem, eszopiclone and zaleplon for serious injuries from complex sleep behaviors; contraindicated after any such episode (library row)
  4. fda drug safety communication, january 2013: risk of next-morning impairment after insomnia drugs; lower recommended doses for zolpidem, women 5 mg immediate-release and 6.25 mg extended-release (library row)
  5. zolpidem and alcohol add; zolpidem and opioids add; st john’s wort and rifampin subtract (ambien prescribing information, drug interactions, april 2025) (library row)
  6. huedo-medina tb, et al. effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the fda. bmj 2012 (library row)
  7. de crescenzo f, et al. comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. lancet 2022 (library row)
  8. treves n, et al. z-drugs and risk for falls and fractures in older adults: a systematic review and meta-analysis. age and ageing 2018 (library row)
  9. national institute for health and care excellence. medicines associated with dependence or withdrawal symptoms (ng215), 2022 (library row)

How long the zolpidem trials actually ran

The longest trial behind the zolpidem approval ran 5 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

People often stay on these drugs for far longer than the trials ran. The trials behind the approval ran from a single night to 5 weeks.

That does not mean longer use is unsafe. It does not mean the drug stops working either. It means longer use was never the thing that got tested.

If you have been on it a long time, that is a fair thing to ask your prescriber about.

Boxed warning: complex sleep behaviors

The strongest warning the FDA puts on a label, often called a black box warning. It is reproduced below word for word, not summarised.

This is the strongest warning the FDA can put on a drug label. Some people call it a black box warning. We copied it word for word. We did not shorten it and we did not soften it.

The warning below is about things people do while they are not fully awake. The label calls these complex sleep behaviors. People have walked and driven in their sleep after taking this drug. They have done other things while not fully awake. Some of those events caused serious injury, including death. The label says to stop the drug at once if this happens.

The FDA’s own words follow, copied exactly.

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN. Some of these events may result in serious injuries, including death. Discontinue AMBIEN immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN. Some of these events may result in serious injuries, including death. Discontinue AMBIEN immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )

FDA label effective April 15, 2025 — read the full label on DailyMed

What zolpidem is FDA approved for, and the trials behind it

Approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation in 1992, under application NDA 019908. Source: FDA Drugs@FDA.

The label describes placebo-controlled trials in both transient and chronic insomnia: a single-night sleep-laboratory trial in 462 normal adults with transient insomnia comparing 7.5 and 10 mg doses with placebo, a 2-night crossover trial in 35 elderly adults, and two chronic-insomnia trials in adult outpatients — 75 patients over 5 weeks and 141 over 4 weeks. In each, zolpidem 10 mg was superior to placebo on measures of sleep latency.

The FDA approved zolpidem in 1992. The approved use was short-term treatment of insomnia. It covers people who have trouble falling asleep. The file number is NDA 019908. The source is Drugs@FDA, the FDA's own database.

The label describes trials against a placebo in two kinds of insomnia, short-lived and long-running.

One sleep-lab trial ran a single night in 462 healthy adults with short-lived insomnia. It compared 7.5 mg and 10 mg with a placebo. A 2-night study gave each of 35 older adults every treatment in turn.

Two trials covered adult outpatients with long-running insomnia. One followed 75 people over 5 weeks. The other followed 141 people over 4 weeks.

In each of them, 10 mg beat the placebo on how long people took to fall asleep.

Trials
2 transient- and 2 chronic-insomnia trials
Duration
1 night to 5 weeks
Participants
35 to 462 patients per trial
Compared against
Placebo
Normal adults experiencing transient insomnia (n=462) during the first night in a sleep laboratory were evaluated in a double-blind, parallel group, single-night trial comparing two doses of zolpidem (7.5 and 10 mg) and placebo. Both zolpidem doses were superior to placebo on objective (polysomnographic) measures of sleep latency, sleep duration, and number of awakenings.

Verbatim from the zolpidem FDA label, Clinical Studies section, effective April 15, 2025 — read the full label on DailyMed.

Side effects of zolpidem in the approval trials

The short-term (up to 10 nights) trials compared 685 patients on zolpidem with 473 on placebo; the fuller list below comes from three longer trials of 28 to 35 nights in chronic insomnia, with 152 patients on zolpidem versus 161 on placebo. The label states these figures cannot be used to predict the incidence of side effects in the course of usual medical practice.

Read the limits first. The short trials ran up to 10 nights. In those, 685 people took the drug and 473 took a placebo.

The fuller list below comes from three longer trials. Those ran 28 to 35 nights in long-running insomnia. In them, 152 people took the drug and 161 took a placebo.

The label says you cannot use these figures to predict side effect rates in ordinary care.

  • Drowsiness (8% vs 5% on placebo)
  • Dizziness (5% vs 1%)
  • Allergy (4% vs 1%)
  • Sinusitis (4% vs 2%)
  • Dry mouth (3% vs 1%)
  • Back pain (3% vs 2%)
  • Lethargy (3% vs 1%)
  • Drugged feeling (3%)
  • Diarrhea (3% vs 2%)
  • Pharyngitis (3% vs 1%)
During short-term treatment (up to 10 nights) with AMBIEN at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were drowsiness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were dizziness (5%) and drugged feelings (3%).

From the zolpidem FDA label, Adverse Reactions section, effective April 15, 2025 — DailyMed.

More from the zolpidem label: drug abuse and dependence

  • Schedule IV controlled substance

    Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.

    FDA label, Drug Abuse and Dependence section.

  • Dependence and withdrawal

    The label states that use of zolpidem may lead to physical and/or psychological dependence, with the risk increasing with dose and duration of treatment and in patients with a history of alcohol or drug abuse. Withdrawal signs and symptoms have followed abrupt discontinuation of sedative/hypnotics, and there have been postmarketing reports of abuse, dependence, and withdrawal with zolpidem.

    FDA label, Drug Abuse and Dependence section.

  • Abuse potential

    In studies of former drug abusers, single doses of zolpidem 40 mg produced effects similar, but not identical, to diazepam 20 mg, while zolpidem 10 mg was difficult to distinguish from placebo. The label advises careful monitoring of patients with a history of addiction to, or abuse of, drugs or alcohol.

    FDA label, Drug Abuse and Dependence section.

How many Americans take zolpidem

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

These are federal survey numbers. They come out about two years late. They count prescriptions filled. They do not tell you if the drug helped.

12,744,221
prescriptions in the United States (2024), refills included
2,420,368
people filling them (2024), ± 430,036 (95%)

Prescriptions are down 43% from 2014 to 2024, a change larger than the survey’s margin of error. Whatever you decide about zolpidem, you are deciding alongside about 2,420,368 other people in 2024.

Prescriptions by year: 2014 22,399,741 · 2015 19,185,054 · 2016 19,102,809 · 2017 15,899,894 · 2018 12,877,941 · 2019 15,419,648 · 2020 14,272,253 · 2021 10,838,845 · 2022 9,972,232 · 2023 11,482,921 · 2024 12,744,221.

Prescriptions are down 43 percent since 2014. About 2.4 million people in the United States took it in 2024.

Correction (29 September 2026). An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves.

Source: AHRQ Medical Expenditure Panel Survey (MEPS), Prescribed Medicines public-use files, 2014 (HC-168A) through 2024 (HC-254A), computed by veisund. People with at least one purchase where the Multum generic name (RXDRGNAM) equals the drug, weighted by the year’s person weight; purchases include refills. Standard errors by Taylor linearization on VARSTR/VARPSU. AHRQ’s reliability rule: a year is not shown when fewer than 60 survey respondents reported the drug or the relative standard error is over 50%. AHRQ cautions that its 2018 questionnaire redesign and the 2020–2022 pandemic years make year-to-year comparisons less certain.

What people report to the FDA about zolpidem

Read this before the numbers.

Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.

Read this before the numbers.

Anyone can send a report to the FDA. Patients can. Doctors can. Drug makers can. Nobody checks that the drug caused what the report describes.

There is also no bottom number. Tens of millions of prescriptions turn into reports at a rate nobody knows. Reports go up when a drug is in the news, and that is not the same as more harm.

So these are counts of reports. They are not rates. You cannot use them to compare one drug with another. The FDA itself says not to use this data to make medical choices.

We show it because it is on the public record, and you should get to see it with its limits named.

134,360
reports mentioning zolpidem, all time
92,984
filed as serious (a report-level flag covering every drug and outcome in the report)
filed as serious. That flag covers the whole report, and one report can name more than one drug and more than one outcome.

Most-reported reactions

  • Drug ineffective8,736
  • Nausea8,545
  • Fatigue8,298
  • Pain6,491
  • Insomnia6,338
  • Headache6,332
  • Diarrhoea5,966
  • Fall5,637
  • Anxiety5,526
  • Dizziness5,296

“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.

It is worth noticing how high “drug ineffective” ranks. A report that the drug did not help counts as an adverse event too. People file a lot of them.

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, openFDA dataset refreshed 2026-07-30 (the refresh date of the query endpoint, not the date reports run through).

Drug interactions listed on the zolpidem label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

Below is the part of the FDA label that lists other drugs. It is copied word for word.

No list on the web can see what else you take. A pharmacist can. Ask one to check your full list.

Read the label’s interactions section

7 DRUG INTERACTIONS CNS depressants, including alcohol: Possible adverse additive CNS-depressant effects ( 5.2 , 7.1 ) Opioids: Concomitant use may increase risk of respiratory depression ( 5.7 , 7.1 ) Imipramine: Decreased alertness observed ( 7.1 ) Chlorpromazine: Impaired alertness and psychomotor performance observed ( 7.1 ) CYP3A4 inducers (rifampin or St. John's wort): Combination use may decrease effect ( 7.2 ) Ketoconazole: Combination use may increase effect ( 7.2 )

7.1 CNS-Active Drugs CNS Depressants Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability [see Warnings and Precautions (5.1 , 5.2 )] . Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. Alcohol An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated [see Warnings and Precautions (5.1 , 5.2) ] . Opioids The concomitant use of AMBIEN with opioids may increase the risk of respiratory depression. Limit dosage and duration of concomitant use of AMBIEN and opioids [see Dosage and Administration (2.3) , Warnings and Precautions (5.7) ] . Imipramine, Chlorpromazine Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance [see Clinical Pharmacology (12.3) ] . Sertraline Concomitant administration of zolpidem and sertraline increases exposure to zolpidem [see Clinical Pharmacology (12.3) ] . Fluoxetine After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance [see Clinical Pharmacology (12.3) ] . Haloperidol A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration [see Clinical Pharmacology (12.3) ] .

7.2 Drugs that Affect Drug Metabolism via Cytochrome P450 Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem. The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known. CYP3A4 Inducers Rifampin Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem and is not recommended [see Clinical Pharmacology (12.3) ] . St. John's wort Use of St. John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when a potent CYP3A4 inhibitor and zolpidem are given together [see Clinical Pharmacology (12.3) ] .

FDA label for zolpidem, effective April 15, 2025 — DailyMed.

Label history: when this label changes, it is recorded in What changed.

Who pays for zolpidem

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D · claims · 2024Medicaid · claims floor · 2024All-payer · survey · 2024Commercially insured adults · not publishedChildren · no per-drug data
Medicare Part D
Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 1,562,877 beneficiaries filled 7,937,736 claims in 2024 — 1,335,962 aged 65 and over, and 226,915 under 65.
Medicaid
At least 1,613,371 prescriptions in 2024 — a floor, because 56 of 422 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.
All payers (survey estimate)
A survey estimate from 170 respondents, which we computed from AHRQ’s MEPS 2024 Prescribed Medicines file (people with at least one purchase, weighted; purchases include refills), puts the whole country at 12,744,221 purchases and 2,420,368 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.
The population nobody counts
The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of zolpidem specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

Who has been paying for zolpidem, 2019–2024

Medicare Part D

Claims, all ages — the one payer with a public per-drug series.

20192024

7,594,066 → 7,937,736 claims

Medicare under 65

Beneficiaries, not ordinary working-age adults: Medicare before 65 means the disabled and dual-eligible population. A gap is a suppressed split, not zero.

20192024

362,098 → 226,915 beneficiaries

Medicaid

A floor each year — small-cell rows are suppressed federally and excluded from the sum.

20192024

2,178,673 → 1,613,371 prescriptions (floor)

Commercially insured adults

No public dataset publishes per-drug commercial claims for any year — the absence is the finding, and it is rendered, not interpolated. The population this library most wants to inform is the one with no public per-drug series, in any year — insurers and PBMs hold that data privately. What the federal surveys do measure — how many adults take these medications at all — is on the adult-usage page.

Sources: Medicare Part D Prescribers by Geography and Drug (data.cms.gov, national rows, per data year); Medicaid State Drug Utilization Data (data.medicaid.gov, national rows). Claims, fills and beneficiaries are different units — compare each series only with itself.

The zolpidem approval, step by step

  1. Step 1

    What the approval was actually based on

    Which studies did the FDA rely on, how long did they run, and who was in them?

    Adult outpatients with chronic insomnia (n=75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.

    FDA-approved labelling, 14 CLINICAL STUDIES 14.2 Chronic Insomnia — read the label on DailyMed

    Our reading

    Read the last sentence twice, because it is the one nobody quotes. Across five weeks in seventy-five people, zolpidem got them to sleep faster than placebo did — and did not reduce how often they woke up. A second trial in 141 outpatients found the benefit on subjective total sleep time, awakenings and sleep quality held for the first treatment week only. This is a drug approved for short-term use on evidence that thins out inside the first month, and the indication says so in as many words.

  2. Step 2

    The approval

    When was it approved, under what application, and by whose review?

    Approved
    December 16, 1992
    Application
    NDA019908
    Review
    STANDARD
    Original sponsor
    Sanofi (now Cosette)
    Holds it now
    Cosette Pharmaceuticals
    Label submissions since
    32

    Source: openFDA Drugs@FDA, original application ORIG-1

  3. Step 3

    What was added after it was on the market

    Which warnings arrived only after millions of people were already taking it?

  4. Step 4

    What independent research has found since

    What has been learned by people who were not selling it?

  5. Step 5

    What still is not known

    Which questions you might reasonably have has nobody answered yet?

    • The approved indication is short-term use. If you have been taking it nightly for years, you are outside both the evidence and the label.
    • Sleep latency improved and number of awakenings did not. Which of those is the problem you are actually trying to solve?
    • The boxed warning for complex sleep behaviours — driving and eating while not fully awake — arrived in 2019, twenty-seven years after approval.
    • What happens to sleep architecture and to rebound insomnia on stopping after long-term use?

The zolpidem legal and safety record

Settled and adjudicated matters only, from primary sources — including the litigation that was decided for the manufacturer, and the cases this drug is verifiably not part of.

Read the zolpidem legal and safety record

Deciding about zolpidem?

Open zolpidem (Ambien) in veisund

The app has the full approval journey, the resources behind it, and people working through the same questions.

Download on the App StoreGet it on Google Play

Browse the evidence library